SERPINA1 and alpha 1-antitrypsin deficiency: Shen and co-authors showed that CRISPR-Cas9 gene-editing technology could impressively decrease AAT-Z liver expression and recover moderate levels of wild-type AAT-M (AAT gene allele M) in an AATD mouse model [108].